International Stem Cell

Dosing of first cohort complete

Development update

Pharma & biotech

27 April 2017

Price	US$1.75
Market cap	US$7m

Net cash ($m) at 31 December 2016		0.1

Shares in issue	3.95m
Free float	46.8%
Code	ISCO

Primary exchange	OTC
Secondary exchange	N/A

Share price performance

%	1m	3m	12m
Abs	(1.7)	60.6	(56.3)
Rel (local)	(3.5)	54.4	(61.7)

52-week high/low

US$3.9

US$0.9

Business description

International Stem Cell is an early-stage biotechnology company developing therapeutic, biomedical and cosmeceutical applications for its proprietary stem form of pluripotent stem cells – human parthenogenetic stem cells (hpSCs). Its lead candidate is a cell therapy treatment for Parkinson’s disease.

Next events

Second cohort enrolment to commence	Q217
Initial efficacy data from first cohort	Q317
Initiation of Phase II in traumatic brain injury	Q317

Analysts

Maxim Jacobs	+1 646 653 7027
Nathaniel Calloway	+1 646 653 7036

healthcare@edisongroup.com

Edison profile page

International Stem Cell is a research client of Edison Investment Research Limited

International Stem Cell recently announced that the first cohort of four patients in its Phase I trial in Parkinson’s disease (PD) had successfully undergone intracranial transplants of ISC-hpNSC. The study will ultimately enroll 12 patients at three dosing regimens (30m-70m cells) with a primary endpoint of safety, but will provide preliminary efficacy data measured at six and 12 months following the treatment.

Year end	Revenue ($m)	PBT* ($m)	EPS* ($)	DPS ($)	P/E (x)	Yield (%)
12/15	7.6	(4.6)	(1.29)	0.0	N/A	N/A
12/16	7.2	(4.9)	(0.34)	0.0	N/A	N/A
12/17e	7.6	(5.9)	(1.47)	0.0	N/A	N/A
12/18e	8.3	(8.2)	(1.96)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding amortization of acquired intangibles, exceptional items and share-based payments.

Parkinson’s trial ongoing

Patients on the study will be treated in three cohorts with 30m, 50m and 70m stem cells, delivered via intracranial injection. The single-arm, open-label study is being conducted at the Royal Melbourne Hospital in Australia. Clinical assessments are scheduled at six and 12 months following surgery the data from this trial will be used in the design of a future Phase II trial expected to initiate in late 2017 or 2018.

Trial will provide first evaluation of efficacy

Besides safety, the trial will also provide physiological and functional assessments of the patients, which will give the first indication of the efficacy of the treatment in humans. Brain function will be directly assessed via PET scan to assess the degree of disease progression. Additionally, patients will be assessed via the six-point Unified Parkinson’s Disease Rating Scale (UPDRS), a qualitative functional scale of a patient’s mental state, muscle tone and ability to perform daily tasks. We expect to see some early efficacy data from the first cohort of patients in Q317.

Preparing to initiate trial in traumatic brain injury

The company is preparing to initiate a Phase II study of ISC-hpNSC in traumatic brain injury (TBI). According to the Centers for Disease Control, TBI accounts for 2.5m emergency room visits in the US annually and approximately 3.2-5.3 million people are living with a TBI-related disability.

Valuation: $28m or $6.97 per basic share

We have updated our valuation from $24m or $7.57 per basic share to $28m or $6.97 per basic share. The total valuation increased primarily due to rolling forward our NPV to 2017 but was mitigated by lower expected peak sales for the commercial business, and a lower cash balance. The per share value declined mainly due to a higher share count. There remain approximately 17.6m potentially dilutive shares from warrants, options and convertible preferred stock. We project that the company will need at least $70m (previously $73m) in additional financing before profitability in 2024, of which $7.5m will be required by the end of 2017.

ISC-hpNSC for Parkinson’s disease

International Stem Cell Corporation has announced that the first cohort of four patients in its Phase I trial in Parkinson’s disease (PD) have successfully undergone intracranial transplant of ISC-hpNSC. It had initiated the Phase I trial of ISC-hpNSC for the treatment of PD in July 2016. ISC-hpNSC are the company’s proprietary neural stem cells (NSC) derived from a human parthenogenetic stem cell line (hpSC). The trial is a dose escalation study designed to evaluate the safety of the intracranial injection of 30m, 50m and 70m cells. The trial is also evaluating the treatment for efficacy by monitoring changes in brain function via PET scan, as well as functional assessment via the UPDRS over the course of 12 months.

The UPDRS is the most common standardized assessment used to monitor the progression and severity of PD in the clinical setting. It comprises six sections, including both patient and clinician evaluation of motor function, mood and the ability to perform daily tasks (Exhibit 1).

Exhibit 1: Unified Parkinson’s Disease Rating Scale

Section	Description	Assessments
1	Mental assessment	Intellectual impairment, thought disorder, depression and initiative
2	Patient scored evaluation of ability to perform daily activities	Hygiene, food preparation, dressing, avoiding falls, speech, tremor etc
3	Clinician scored motor assessment	Measures of function (tremor, rigidity, posture), functional assessments (ability to rise from a chair, gait, speech) and evaluation of specific muscle groups (fingers, face, legs)
4	Complications associated with therapy	Rate of dyskinesia, assessments of “off” periods, other complications of treatment (nausea, insomnia, etc)
5	The Modified Hoehn Yahr Staging	Global evaluation ranging from no visible signs of disease to wheelchair-bound state
6	Schwab & England Activities of Daily Living Scale	Degree of independence from care givers ranging from completely independent to inability to swallow or perform bowel movements

Source: National Parkinson Foundation

The study is being performed at the Royal Melbourne Hospital in Australia and has a targeted enrolment of 12 moderate to severe PD patients, with the second cohort expected to start enrolment in Q217 following a meeting of the Data Safety Monitoring Board at the beginning of May. We expect to see some early efficacy data from the first cohort of patients in Q317

PD affects 7-10 million people worldwide, with approximately 1.5 million in the US. The most widespread treatment for the disease is the combination of levodopa and carbidopa, which provides the brain with dopamine lost by the death of dopaminergic neurons. The majority of clinical development in the space has been focused on the reformulation of this and other treatment regimens and, to date, no disease-modifying therapies have been approved.

Moving into traumatic brain injury

The company recently announced plans to start a Phase II study of ISC-hpNSC for the treatment of traumatic brain injury (TBI) following preclinical results in rodents suggesting the therapy can improve cognitive performance and motor co-ordination in those with the condition. We expect the company to conduct the Phase II trial in Australia where it would only need Ethics Committee approval to start the trial. Also, once Phase II data are in hand, we would expect the company to apply to the FDA for the new Regenerative Medicine Advanced Therapy (RMAT) designation, which came into existence as part of the 21st Century Cures Act. Sponsors of regenerative medicine products, like ISC-hpNSC, may obtain the designation if the drug is intended to treat a serious or life-threatening condition and there is some preliminary clinical evidence of the ability to address unmet medical needs for that condition. RMAT designation allows for increased interactions with the FDA, similar to the interactions available to those with breakthrough designation, and the company may also become eligible for priority review and accelerated approval.

According to the Centers for Disease Control, TBI accounts for 2.5m emergency room visits in the US annually and approximately 3.2-5.3 million people are living with a TBI-related disability with no effective long-term treatments outside of rehabilitation. Given the size, TBI could be as meaningful to the company as PD, for which we currently forecast $2.8bn in peak sales. We expect the company to report on a dose-escalating animal study in the coming months and initiate the Phase II study in Q317.

Valuation

We have updated our valuation from $24m or $7.57 per basic share to $28m or $6.97 per basic share. The total valuation increased primarily due to rolling forward our NPV to 2017 but was mitigated by lower expected peak sales for the commercial business, and a lower cash balance. The per share value declined mainly due to a higher share count (much of it due to a 926,971 warrant exercise). There remain approximately 17.6m potentially dilutive shares from warrants, options and convertible preferred stock. We expect to review our valuation following the release of efficacy data in Parkinson’s as well as additional detail regarding the traumatic brain injury program.

Exhibit 2: Risk-adjusted NPV valuation model

Product	Status	Launch	Peak sales ($m)	NPV ($m)	Probability	rNPV ($m)	NPV/share ($/share)
Cosmetic and Biomedical Business	Commercial	Current	18	24	90%	21	5.39
Parkinson’s Disease (royalties at 12% of sales)	Phase I/IIa	2024	2,800	459	7.5%	34	8.72
G&A expense – after tax					100%	(28)	(7.17)
Net cash					100%	0.1	0.03
Valuation						28	6.97

Source: Edison Investment Research estimates

Financials

International Stem Cell reported 2016 revenues of $7.2m, down 5.1% compared to 2015. The biomedical business continues to grow with revenues of $4.3m, up 6.6% compared to last year, but the cosmetics business was down 18.7%. For the company as a whole, the operating loss was $4.9m for the year. We have adjusted our model to reflect weaker commercial sales than we had forecast as well as slightly lower SG&A expenses. The company reported only $110,000 in cash as of the end of Q4, though has subsequently raised $1.3m through a promissory note issued to the CEO. It has a 3.5% annual coupon that is payable on 1 September 2017.

Exhibit 3: Changes to estimates

$000s	Revenue			Operating profit			Profit after tax
$000s	Old	New	% change	Old	New	% change	Old	New	% change
2017e	8,311	7,593	(8.6%)	(5,130)	(5,290)	(3.1%)	(5,970)	(5,890)	1.3%
2018e	9,156	8,341	(8.9%)	(6,749)	(6,958)	(3.1%)	(8,189)	(8,158)	0.4%

Source: Edison Investment Research. Note: Operating profit and profit after tax exclude amortization of acquired intangibles, exceptional items and share-based payments.

We project that the company will need at least $70m (previously $73m) in additional financing before profitability in 2024, of which $7.5m will be required by the end of 2017.

Exhibit 4: Financial summary

	US$000	2013	2014	2015	2016	2017e	2018e
Year end 31 December		US GAAP	US GAAP	US GAAP	US GAAP	US GAAP	US GAAP
PROFIT & LOSS
Revenue		6,147	7,017	7,551	7,165	7,593	8,341
Cost of Sales		(1,643)	(1,921)	(2,056)	(1,944)	(2,050)	(2,169)
Gross Profit		4,504	5,096	5,495	5,221	5,543	6,172
Research and development		(3,560)	(5,386)	(2,707)	(2,856)	(4,000)	(6,000)
EBITDA		(8,010)	(9,138)	(5,036)	(5,182)	(5,621)	(7,289)
Operating Profit (before amort. and except.)		(7,546)	(8,680)	(4,564)	(4,851)	(5,290)	(6,958)
Intangible Amortization		0	0	0	0	0	0
Exceptionals		0	0	0	0	0	0
Other		(2,930)	(3,796)	1,929	3,772	0	0
Operating Profit		(10,476)	(12,476)	(2,635)	(1,079)	(5,290)	(6,958)
Net Interest		(3)	(2)	0	0	(600)	(1,200)
Profit Before Tax (norm)		(7,549)	(8,682)	(4,564)	(4,851)	(5,890)	(8,158)
Profit Before Tax (reported)		(10,479)	(12,478)	(2,635)	(1,079)	(5,890)	(8,158)
Tax		0	0	0	0	0	0
Profit After Tax (norm)		(10,479)	(12,478)	(2,635)	(1,079)	(5,890)	(8,158)
Profit After Tax (reported)		(10,479)	(12,478)	(2,635)	(1,079)	(5,890)	(8,158)

Average Number of Shares Outstanding (m)		0.8	1.3	2.0	3.2	4.0	4.2
EPS - normalised (US$)		(12.77)	(9.71)	(1.29)	(0.34)	(1.47)	(1.96)
EPS - normalised fully diluted (US$)		(12.77)	(9.71)	(1.29)	(0.34)	(1.47)	(1.96)
EPS - (reported) (US$)		(12.77)	(9.71)	(1.29)	(0.34)	(1.47)	(1.96)
Dividend per share (US$)		0.0	0.0	0.0	0.0	0.0	0.0

Gross Margin (%)		73.3	72.6	72.8	72.9	73.0	74.0
EBITDA Margin (%)		N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin (before GW and except.) (%)		N/A	N/A	N/A	N/A	N/A	N/A

BALANCE SHEET
Fixed Assets		3,113	3,563	4,147	4,553	5,087	5,636
Intangible Assets		2,250	2,795	3,223	3,484	4,032	4,579
Tangible Assets		830	714	864	1,011	997	999
Investments		33	54	60	58	58	58
Current Assets		4,626	3,616	2,991	2,492	4,797	4,670
Stocks		1,369	1,517	1,348	1,390	1,356	1,489
Debtors		306	453	539	574	542	595
Cash		2,243	1,111	532	110	2,482	2,168
Other		708	535	572	418	418	418
Current Liabilities		(7,021)	(6,858)	(5,544)	(3,601)	(3,858)	(3,966)
Creditors		(7,021)	(6,858)	(5,544)	(3,601)	(3,858)	(3,966)
Short term borrowings		0	0	0	0	0	0
Long Term Liabilities		0	0	0	0	(7,500)	(15,000)
Long term borrowings		0	0	0	0	(7,500)	(15,000)
Other long term liabilities		0	0	0	0	0	0
Net Assets		718	321	1,594	3,444	(1,474)	(8,660)

CASH FLOW
Operating Cash Flow		(5,638)	(6,413)	(4,120)	(4,197)	(3,663)	(5,734)
Net Interest		(3)	(2)	0	0	(600)	(1,200)
Tax		0	0	0	0	0	0
Capex		(896)	(988)	(738)	(944)	(865)	(880)
Acquisitions/disposals		0	0	0	0	0	0
Financing		8,123	6,270	1,169	4,018	0	0
Dividends		0	0	0	0	0	0
Net Cash Flow		1,586	(1,133)	(3,689)	(1,123)	(5,128)	(7,814)
Opening net debt/(cash)		(654)	(2,243)	(1,111)	(532)	(110)	5,018
HP finance leases initiated		0	0	0	0	0	0
Other		0	1	3,110	701	0	0
Closing net debt/(cash)		(2,243)	(1,111)	(532)	(110)	5,018	12,832

Source: Edison Investment Research, International Stem Cell reports

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by International Stem Cell and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2017. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

Sydney +61 (0)2 8249 8342

Level 12, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

Sydney +61 (0)2 8249 8342

Level 12, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

Sydney +61 (0)2 8249 8342

Level 12, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

Sydney +61 (0)2 8249 8342

Level 12, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Equities

Equities by Sector

Sectors

Investment Strategy

Latest

Equity strategy and market outlook – March 2024

Equity strategy and market outlook – February 2024

Equity strategy and market outlook – January 2024

Thematics

Latest

Listed private equity – Performing a balancing act

ConsumerWatch – At least someone loves me

MediaWatch – Rinse and repeat

Audiovisual

Latest

IP Group – executive interview

Take on Trusts – March 2024

Oakley Capital Investments – executive interview

About Edison

About Edison

Careers

International Stem Cell — Dosing of first cohort complete

Latest

discoverIE Group — FY24 EPS in line; good margin progress

Ultimovacs — Steadfast commitment to UV1 progression

OSE Immunotherapeutics — AbbVie deal clears antitrust hurdle

Jersey Electricity — Decarbonisation fuelling growth

Foxtons Group — FY24 underpinned by market share gains

Canadian General Investments — ‘One-stop-shop’ for investment in Canada

Subscribe to Edison